nodes	percent_of_prediction	percent_of_DWPC	metapath
Linezolid—MAOA—Clearance of dopamine—SLC6A3—Gilles de la Tourette syndrome	0.379	0.379	CbGpPWpGaD
Linezolid—MAOA—Biogenic Amine Synthesis—HDC—Gilles de la Tourette syndrome	0.301	0.301	CbGpPWpGaD
Linezolid—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.173	0.173	CbGpPWpGaD
Linezolid—MAOB—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.0934	0.0934	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.0132	0.0132	CbGpPWpGaD
Linezolid—MAOB—Metabolism—HDC—Gilles de la Tourette syndrome	0.0116	0.0116	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.0111	0.0111	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.0101	0.0101	CbGpPWpGaD
Linezolid—MAOA—Metabolism—HDC—Gilles de la Tourette syndrome	0.00731	0.00731	CbGpPWpGaD
